Endocrine Abstracts

Introduction: Whilst effective, targeted checkpoint inhibitor monoclonal antibodies are associated with immune-related adverse events including endocrinopathies. Increased licensed oncological indications for these agents raise the need for effective screening, monitoring and ongoing treatment of endocrinopathies. The aim of our study was to investigate potential predictive factors that may identify patients at risk of endocrinopathies....

Introduction: Whilst effective, targeted checkpoint inhibitor monoclonal antibodies are associated with immune-related adverse events including endocrinopathies. Increased licensed oncological indications for these agents raise the need for effective screening, monitoring and ongoing treatment of endocrinopathies. The aim of our study was to investigate potential predictive factors that may identify patients at risk of endocrinopathies....

Background: Immune checkpoint inhibitors (ICIs), approved in the UK for the treatment of increasingly numerous malignancies, are commonly associated with endocrine sequelae, some of which may be life threatening. Society for Endocrinology guidelines detail management protocols for acute endocrinopathies, however widely accepted standards for their routine detection are lacking. Hypophysitis, clinically and radiologically silent in many, is seen in up to 15% of patients on ICIs...

Introduction: Hypophysitis (Hp) is a serious adverse effect (AE) of Immune check-point inhibitor (ICI) therapy in malignancy. We evaluated 6 yeas of clinical expereince with ICI against the recent ESE CPG 2023 which provides practical guidance on the management of this condition based on up-to-date evidence.Methods: A quality improvement project (QIP) included all patients with ICI-Hp (n=17) referred to a dedicated Endocrine-ICI clinic (January ...